Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 2,96 € (+228,89 %). La médiane est de 2,96 € (+228,89 %).

Acheter
  6
Conserver
  1
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Product recall weighs on Biote Q1: profit and revenue below expectations

    Biote reports Q1 2026 EPS of $0.06 (expectation $0.10) and revenue of $44.9m (expectation $46.01m), mainly impacted by a voluntary recall of bioidentical hormone pellets. Revenue fell 8.3% year over year, treatment revenues declined 13.2%, while supplements rose 19.1% thanks to e‑commerce. The stock fell 5.43% in after‑hours trading. Despite the disruption, management reaffirms the full‑year guidance of >$190m in revenue and >$38m in adjusted EBITDA and expects a recovery in the second half of the year. » Plus sur de.investing.com


  • Biote misses Q1 forecasts: EPS and revenue fall short of expectations

    Biote reported Q1 2026 earnings of $0.06 per share versus $0.10 expected and revenue of $44.9 million versus $46.01 million expected. Revenue fell 8.3% year‑on‑year, weighed down by a voluntary recall of bioidentical hormone pellets, while the supplements segment grew 19.1%. Management maintains its full‑year revenue guidance of over $190 million and expects treatment revenues to recover in the second half of the year. After the release, the stock fell 0.45% to $2.21. » Plus sur de.investing.com


  • Biote Corp misses Q4 2025 earnings forecast and reports revenue decline

    Biote Corp reported Q4 2025 EPS of $0.06, missing the $0.09 estimate; revenue was $46.4 million, slightly below the expected $47.12 million. The supplement business grew 16% thanks to e‑commerce, but could not offset declines in treatment revenue and higher clinic churn. Gross margin fell due to inventory charges following a recall; the company expects treatment revenue headwinds through the first half of 2026 and growth in the supplement segment later in the year. » Plus sur de.investing.com


  • Biote Corp. subsidiary Asteria Health recalls hormone pellets over metal particle risk

    Biote Corp. said its subsidiary F.H. Investments, operating as Asteria Health, has initiated a voluntary recall of certain batches of compounded bioidentical hormone pellets shipped between May 20, 2025 and January 19, 2026. The recall is due to potential contamination with metal particles and is being conducted with knowledge of the FDA. Biote expects a one‑time charge of about $1.3 million in the fourth quarter for write‑down of affected inventory and estimates additional recall costs for 2026 of roughly $1 million. The company does not expect significant further impact on supply to partner clinics and will disclose details of the financial effects with its Q4 results. » Plus sur de.investing.com


  • biote posts Q3 EPS 371% above forecasts; analysts trim 2026 EPS and price target

    biote reported Q3 revenue of US$48m in line with expectations and statutory EPS of US$0.22, 371% above forecasts. After the results analysts left 2026 revenue estimates roughly unchanged at US$198.4m but cut consensus EPS to US$0.32 from US$0.34. The average price target fell 5.6% to US$4.61, and analysts now expect biote’s revenue growth to slow materially below industry peers. » Plus sur finance.yahoo.com

Données financières de l'entreprise

Au dernier trimestre, Biote Corp a réalisé un chiffre d'affaires de 38,26 M € et un bénéfice net de 359,32 k €
(EUR) septembre 2026
YoY
Chiffre d'affaires 38,26 M 6,38 %
Bénéfice brut 25,89 M 11,71 %
Bénéfice net 359,32 k 94,85 %
EBITDA 3,98 M 61,49 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
39,79 M €
Nombre d'actions
44,11 M
Plus haut/bas sur 52 semaines
2,64 € - 0,87 €
Dividendes Non
Bêta
1,74
Ratio P/E
-12,84
Ratio PEG
0,12
Ratio P/B
-0,41
Ratio P/S
0,24

Profil de l'entreprise

Biote Corp. exerce dans le domaine du développement de cabinets médicaux, au sein du secteur de l'optimisation hormonale. La société propose une plateforme permettant aux praticiens certifiés Biote d'optimiser les déséquilibres des niveaux hormonaux, vitaminiques et minéraux de leurs patients, ainsi que de prescrire des traitements hormonaux bio-identiques et de recommander des compléments alimentaires. Elle commercialise également des compléments alimentaires de la marque Biote ainsi que des kits d'insertion de granulés stériles destinés aux hommes et aux femmes. La société a été fondée en 2011 et a son siège social à Irvine, au Texas.

Nom
Biote Corp
PDG
Robert C. Peterson
Siège social Irving, tx
États-Unis
Site web
Secteur
Santé
Industrie
Prestataires et services de santé
Introduction en bourse
28/04/2021
Employés 223

Symboles boursiers

Bourse Symbole
Pnk
BTMD
🍪

Parqet  utilise des cookies. En savoir plus